ESTRO 2023 - Abstract Book

S1292

Digital Posters

ESTRO 2023

and vitamin E have shown potential to alleviate RIF. Here is reported an investigation of the effect of pentoxyfylline/vitamin E on RIF in BC & HNC patients treated at a single institute. Materials and Methods All BC & HNC patients treated and evaluated during 2016-2021 with pentoxyfylline/vitamin E for RIF at one center were identified retrospectively. Data was extracted from patient files, and all patients were handled by two consultants (BC (BV0) & BC + HNC (CNA). Therapy was oral Pentoxifylline 400mg and vitamin E 300 IE twice daily. Objective induration in the irradiated area (preferably biopsy-proven) was a prerequisite for therapy. Main endpoint was length of treatment beyond 6 months which was considered a surrogate marker of clinical benefit deemed by either the patient and/or the consultant. Results In total, 55 patients were referred for treatment, which was initiated in 47 patients (27 BC & 20 HNC patients). Five BC patients were lost to follow-up, whilst two HNC patients stopped treatment shortly after treatment start because of side effects, thus 40 patients were treated and evaluated. Median duration from end of radiation therapy to RIF was 30 months (BC) and 46 months (HNC). Overall, 22 BC patients were treated and 17 had clinical partial or complete response. Among 18 HNC patients, five patients had effect of the treatment. Side-effects from treatment were modest with one patient discontinuing treatment because of gastrointestinal symptoms with nausea and diarrhea and one because of headache and concentration difficulty. One BC patient who had had effect of the treatment was discontinued after approximately 9 months because of a small retina bleeding without sequelae.

Conclusion Pentoxifylline and vitamin E is a cheap and well-tolerated treatment and also an effective treatment in a considerable number of patients for an otherwise substantial side-effect to radiation therapy. The effect seems in our study to be more pronounced within the BC patients compared to the HNC group, but patients in both groups have benefit of the treatment. More studies are needed to investigate whether our findings also can be reproduced in larger populations and also to gain more knowledge of which patients will have benefit of the treatment and who will not.

PO-1592 A Phase I Study Evaluating the Safety of SCART for Bulky metastatic or recurrent Cancer

W. Yan 1 , Q. Lu 2 , W. QI 2 , S. Li 2 , Y. Li 2 , L. Wang 2 , L. Han 2,3 , Z. Shi 4 , S. Tubin 5 , W. Mourad 6 , X. Wu 7 , Y. Lin 8 , J. Yang 9

1 University Of Kentucky, Radiation Oncology, Lexington , USA; 2 Foshan Chancheng Hospital, Radiation Oncology, Foshan, China; 3 Junxin Oncology Group, Radiation Oncology, Foshan, China; 4 Texas Tech University Health Sciences Center, Radiation Oncology, Lubbock, USA; 5 Medaustron Center for Ion Therapy and Research, Radiation Oncology, Vienna, Austria; 6 University of Kentucky, Radiation Oncology, Lexington, USA; 7 Biophysics Research Institute of America, Radiation Oncology, Miami, USA; 8 Taichung veterans general hospital, Radiation Oncology, Taichung, Taiwan; 9 Junxin Oncology Group, Radiation Oncology, Foshan, USA Purpose or Objective Purpose: SFRT (Spatially fractionated radiation therapy (SFRT) is important in its concept of covering whole or partial tumors with inhomogeneous radiation doses and gives the field more creativity and complimentary applications to supplement the standard school of radiation therapy. SFRT, such as GRID therapy, has been shown to offer benefits in bulky